Rongrong Yang | Medicine | Best Researcher Award

Prof. Rongrong Yang | Medicine | Best Researcher Award

Zhongnan Hospital of Wuhan University | China

Prof. Yang Rongrong, M.D., serves as a Chief Physician, Associate Professor, and Master’s Supervisor, with an esteemed career in infectious disease prevention, particularly in HIV/AIDS occupational exposure management. With numerous national and provincial research leadership roles and active involvement in academic and peer review, she stands out as a leading voice in public health research and medical education in China.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Distinguished Research Leadership:
    Dr. Yang has led multiple competitive and prestigious research projects, including funding from the National Natural Science Foundation of China, Hubei Provincial bodies, and Wuhan University. This reflects a high level of trust in her scientific capabilities and leadership.

  • High-impact Publications:
    With 52 professional papers, 29 of which are SCI-indexed, and a cumulative impact factor of 206.586, Dr. Yang demonstrates significant scholarly contribution in the field of infectious diseases. This publication record shows consistency, quality, and depth.

  • Expert Recognition and Peer Review Contributions:
    Her role as a peer reviewer for numerous high-impact SCI journals (e.g., iScience, Frontiers, PLOS ONE) and as a thesis review expert for the Ministry of Education highlights her academic reputation and recognition by the broader scientific community.

  • Public Health Relevance:
    Her focus on HIV/AIDS prevention and occupational exposure is of critical importance to public health. Her work bridges clinical medicine and public health, offering real-world impact.

  • Mentorship and Academic Service:
    As a Master’s supervisor and associate professor, Dr. Yang contributes significantly to academic training and capacity building in medical sciences.

🎓 Education

Dr. Yang holds a Doctor of Medicine degree and has advanced through the academic ranks, distinguished by her role as a Degree Thesis Review Expert for the Academic Degree Center of the Ministry of Education, reflecting her academic rigor and dedication to mentoring postgraduate students.

🧑‍🔬 Experience

Dr. Yang is a Medical Science Research Project Review Expert for Wuhan City, and actively serves as a peer reviewer for high-impact SCI journals including iScience, PLOS ONE, Frontiers in Public Health, and Risk Management and Healthcare Policy. Her influence in clinical medicine is matched by her engagement in policy and program-level evaluations across provincial and national platforms.

🔬 Research Interests On Medicine

Her primary research focus is the prevention and treatment of infectious diseases, with an emphasis on HIV/AIDS and occupational exposure. She contributes significantly to public health strategies through translational research, applying scientific findings to real-world clinical and preventative practices.

🏆 Awards & Recognitions

Dr. Yang has led several high-profile research projects:

  • National Natural Science Foundation of China (Grant No. 82003511)

  • Youth Talent Project, Hubei Provincial Health and Family Planning Commission (WJ2015Q0192)

  • Key Project, Hubei Provincial Center for Disease Control and Prevention

  • Independent Research Grant, Wuhan University
    These recognitions underscore her role as a Principal Investigator and emerging leader in public health innovation.

📚 Publications

Dr. Yang has authored 52 professional papers, with 29 SCI-indexed works contributing to a total impact factor of 206.586. Below are some of her notable publications with citation data:

  1. Yang, R. et al. (2023). “Evaluation of occupational exposure control in HIV-prone environments.” Frontiers in Public Health. LinkCited by 12 articles

  2. Yang, R. et al. (2022). “Innovative HIV prevention strategies for healthcare workers.” PLOS ONE. LinkCited by 20 articles

  3. Yang, R. et al. (2021). “Case report on pediatric HIV exposure.” Frontiers in Pediatrics. LinkCited by 7 articles

  4. Yang, R. et al. (2020). “Public health surveillance and HIV: A real-time case study.” JMIR Public Health and Surveillance. LinkCited by 15 articles

  5. Yang, R. et al. (2019). “Risk analysis of healthcare settings in HIV/AIDS exposure.” Risk Management and Healthcare Policy. LinkCited by 18 articles

🔚 Conclusion

With a distinguished portfolio of clinical practice, academic service, and research leadership, Dr. Yang Rongrong has made a significant impact in infectious disease control and occupational health safety. Her contribution to medical science is not only academic but also societal, shaping public health policies and clinical standards in China and beyond.

Guoli Li | Medicine | Best Researcher Award

Dr. Guoli Li | Medicine | Best Researcher Award

Researcher | Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University) | China

Dr. Guoli Li, Ph.D., is an Assistant Professor at Hunan Provincial People’s Hospital and the First Affiliated Hospital of Hunan Normal University, located in Changsha, China. With expertise in Molecular Medicine, Cancer Research, and Nephrology, Dr. Li has contributed extensively to the scientific community, focusing on cutting-edge advancements in medical research.

Profile

Google Scholar

Strengths for the Awards

  • Extensive Research Background:
    Dr. Guoli Li has a strong academic and research foundation in molecular medicine, cancer research, and nephrology, with significant experience at reputable institutions like the University of Texas MD Anderson Cancer Center and Hunan Normal University.
  • Diverse Publication Record:
    Dr. Li has authored numerous high-impact publications in peer-reviewed journals such as Frontiers in Oncology, Genes and Diseases, and BMC Nephrology. These papers cover critical topics like cancer biomarkers, glomerulopathy, and ferroptosis in cancer, demonstrating expertise in innovative and clinically relevant research.
  • Bibliometric Contributions:
    Contributions to bibliometric studies (e.g., research on ferroptosis and mitophagy) highlight Dr. Li’s ability to analyze global research trends, adding to their scholarly influence.

Education 🎓

  • Ph.D. in Biochemistry and Molecular Biology (2013–2017)
    Central South University, Changsha, Hunan, China
  • B.S. in Biotechnology (2008–2012)
    Changchun University of Technology, Changchun, Jilin, China

Experience 💼

  • Research Scientist (09/2020–Present)
    Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, Hunan, China
  • Postdoctoral Fellow (09/2018–08/2020)
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Instructor (06/2018–06/2020)
    Guangzhou Medical University, Guangzhou, Guangdong, China
  • Technician (08/2012–08/2013)
    Sansure Biotech Inc., Changsha, Hunan, China

Research Interests On Molecular Medicine🔬

Dr. Li’s research spans:

  • Molecular mechanisms in cancer biology 🧬
  • Nephrology, focusing on lupus nephritis and glomerulopathy 🩺
  • Biomarker identification and therapeutic development 🚑

Awards 🏆

  • 2018: Outstanding Graduate
  • 2016-2017: Excellent Graduate Student
  • 2009-2010: Excellent Student and Excellent Student Leader

Publications 📚

  • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
    Authors: G Li, X Guo, L Tang, M Chen, X Luo, L Peng, X Xu, S Wang, Z Xiao, W Yi, …
    Year: 2017
    Citations: 43
  • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
    Authors: G Li, X Guo, M Chen, L Tang, H Jiang, JX Day, Y Xie, L Peng, X Xu, J Li, …
    Year: 2018
    Citations: 39
  • What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
    Authors: W Wang, H Liu, G Li
    Year: 2022
    Citations: 26
  • Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients
    Authors: J Heng, X Guo, W Wu, Y Wang, G Li, M Chen, L Peng, S Wang, L Dai, …
    Year: 2017
    Citations: 20
  • The research landscape of ferroptosis in cancer: a bibliometric analysis
    Authors: G Li, Y Liang, H Yang, W Zhang, T Xie
    Year: 2022
    Citations: 17
  • Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
    Authors: Y Xie, G Li, M Chen, X Guo, L Tang, X Luo, S Wang, W Yi, L Dai, J Wang
    Year: 2018
    Citations: 16
  • Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients
    Authors: T Xie, M Chen, X Tang, H Yin, X Wang, G Li, J Li, X Zuo, W Zhang
    Year: 2016
    Citations: 16
  • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
    Authors: H Deng, M Chen, X Guo, J Heng, X Xu, L Peng, H Jiang, G Li, JX Day, J Li, …
    Year: 2019
    Citations: 11
  • Bibliometric insights of global research landscape in mitophagy
    Authors: G Li, W Yin, Y Yang, H Yang, Y Chen, Y Liang, W Zhang, T Xie
    Year: 2022
    Citations: 10
  • LINC00467 is upregulated by DNA copy number amplification and hypomethylation and shows ceRNA potential in lung adenocarcinoma
    Authors: W Wang, H Bo, Y Liang, G Li
    Year: 2022
    Citations: 9

Conclusion 📝

Dr. Guoli Li is a passionate scientist and educator committed to advancing medical research and improving clinical outcomes. With numerous prestigious publications, awards, and invitations as a reviewer for reputed journals, Dr. Li continues to contribute profoundly to the global research community. 🌐